Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush

Wedbush assumed coverage on shares of Climb Bio (NASDAQ:CLYM) in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $12.00 price objective on the stock.

Several other analysts have also issued reports on the stock. Piper Sandler assumed coverage on shares of Climb Bio in a research report on Friday, February 13th. They issued an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. Wall Street Zen cut Climb Bio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Finally, HC Wainwright boosted their price objective on Climb Bio from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Climb Bio has an average rating of “Moderate Buy” and a consensus price target of $10.60.

Climb Bio Price Performance

Shares of NASDAQ:CLYM opened at $7.18 on Thursday. The business’s 50 day moving average price is $5.20 and its 200-day moving average price is $3.32. Climb Bio has a 1 year low of $1.05 and a 1 year high of $7.59. The firm has a market capitalization of $489.53 million, a price-to-earnings ratio of -8.07 and a beta of -0.25.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). On average, sell-side analysts expect that Climb Bio will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other Climb Bio news, Director Ra Capital Management, L.P. bought 213,099 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $2.18 per share, with a total value of $464,555.82. Following the purchase, the director directly owned 3,294,856 shares of the company’s stock, valued at $7,182,786.08. This trade represents a 6.91% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have purchased 321,672 shares of company stock valued at $779,626. Company insiders own 0.80% of the company’s stock.

Institutional Investors Weigh In On Climb Bio

Large investors have recently made changes to their positions in the stock. MPM Bioimpact LLC purchased a new position in Climb Bio during the fourth quarter worth approximately $10,686,000. Price T Rowe Associates Inc. MD grew its holdings in Climb Bio by 265.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock valued at $7,695,000 after buying an additional 1,396,722 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in shares of Climb Bio by 972.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after acquiring an additional 1,298,945 shares during the last quarter. Sphera Funds Management LTD. increased its stake in shares of Climb Bio by 114.4% in the 4th quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock worth $3,729,000 after acquiring an additional 497,410 shares during the last quarter. Finally, Diadema Partners LP raised its holdings in shares of Climb Bio by 4.8% during the 2nd quarter. Diadema Partners LP now owns 702,135 shares of the company’s stock worth $871,000 after acquiring an additional 32,332 shares during the period. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Wedbush initiated coverage with an “outperform” rating and a $12 price target, providing analyst endorsement that implies significant upside from current levels. Wedbush Initiates Coverage
• Positive Sentiment: Robert W. Baird raised its price target from $9 to $12 and assigned an “outperform” rating, echoing bullish analyst sentiment and adding upward price-target momentum. Baird Price Target Raise
• Positive Sentiment: Company operational update: dosing completed in a Phase 1 subcutaneous study of budoprutug, multiple clinical trials ongoing (pMN, ITP, SLE) with initial data expected H1–H2 2026, ongoing enrollment in CLYM116 Phase 1; management says cash runway extends into 2028 — these milestones support medium-term value if data readouts are positive. Press Release
• Neutral Sentiment: Short-interest reports in early March show zero reported short positions and a 0.0 days-to-cover figure, which appears to be a data anomaly (NaN/inconsistent reporting) and likely has limited informational value until clarified.
• Negative Sentiment: Climb reported Q4 EPS of ($0.26), missing the consensus ($0.20) by $0.06 — a clear near-term negative that likely pressured the stock as investors digest lower-than-expected profitability metrics. Earnings Release

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.